US and EU members of the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) have recognized the need for a workshop aimed at identifying factors negatively impacting the development, approval, introduction and appropriate use of new diagnostic tools for invasive bacterial infections in both inpatient and outpatient settings. It also addressed the role of diagnostic tools in the development of novel antibacterials and the challenges in the development of companion diagnostics by drug developers.
The intended outcomes of the workshop were the identification of existing barriers and possible solutions in the following areas:
1. Factors limiting the development and use of contemporary diagnostic tools
2. Identification of key partners that need to join the effort to advance diagnostics into clinical practice
3. The role of improved diagnostic tests in enhancing clinical development of novel antimicrobials
The workshop took place on September 28 and 29, 2011, in Brussels.
A summary of the meeting outcomes will be published soon.
The keynote sessions participants were:
- Donald Low, MD - Setting the stage: significance and need for rapid diagnostic tests for invasive bacterial infections
- Rosanna Peeling, PhD - Review of candidate technologies
- John Rex, MD - The importance of rapid diagnostics for advancing antibacterial development
The subjects of the scientific sessions were:
- Session 1: Technical and scientific challenges in the development of rapid diagnostics
- Session 2: Regulatory challenges in the development of new diagnostic tests
- Session 3: Economic factors impacting the development of novel rapid diagnostics
- Session 4: Challenges in the acceptance and adoption of new diagnostic tests